Login

I cannot remember my username

Our New Website Is Here!
As part of our merger with St. Paul Research, we’ve created a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through our analysts’ combined insight, expertise, and perspective. Go to my.stpaulresearch.com to access our new site.

Ray Blanco’s FDA Profit Alert

Ray Blanco's FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

Flash Buy! Big Buy Opportunity for This Cancer Therapy Developer

Ray Blanco
By Ray BlancoPosted January 20, 2021

2021 is building into a big year for the play today. The small cancer therapy developer has already racked up three FDA approvals, with the latest in multiple myeloma granted last month.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Ray Blanco’s FDA Profit Alert

The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Ray Blanco

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Related Posts

Flash Alert: Sell These Two Plays ASAP

Ray Blanco
By Ray BlancoPosted September 2, 2020

When a biotech company reports strong clinical results for a therapy in development, prices can soar. But when an experimental drug fails to clear the bar, prices can move sharply the other way. Today we have two plays we’re exiting ASAP to free up our portfolio for better future opportunities. Plus, one play that’s at a great value right now!